The pain, nausea, and vomiting endured by a patient undergoing chemotherapy can be extremely debilitating. The number of medications that the healthcare industry provides today can help with CINV, but do very little to negate the symptoms. 2012 witnessed nearly 14.1 million people being diagnosed with cancer, in comparison to the 12.7 million in 2008. With the current rate in mind, the number is expected to reach 17.1 cancer patients by 2020. Their growing numbers will generate a high demand from the healthcare industry for chemotherapy and related markets, including the CINV drugs segment. With almost 70% to 80% of chemotherapy patients experiencing nausea and vomiting, it has become imperative to create stark improvements in the CINV existing and pipeline drugs market.
Browse Full Global CINV Existing and Pipeline Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/cinv-market.html
CINV Existing and Pipeline Drugs Market Segmentation
The single strongest point of differentiation in the market today is the association of major drugs with their revenues earned. The list includes:
Kytril Generic (granisetron)
Zofran Generic (ondansetron)
SUSTOL (extended release granisetron injection)
Rolapitant and SUSTOL (APF-530) are newly approved drugs that are set to drive the CINV drugs market till 2020. They show a far stronger efficacy than the current line of CINV drugs, in terms of their medical trials. Their launch is expected to provide a boost to the CINV drugs market and encourage physicians to prescribe the new drugs with a higher confidence.
One the other hand, drugs such as Aloxi and Emend are about to lose their patents to expiration. This will have a significant impact on the CINV existing and pipeline drugs market, which will be flooded with generic drugs with the same chemical formula. The market’s revenue is expected...